TY  - JOUR
AU  - Colombo, M.
AU  - Fernández Vázquez, María Inmaculada
AU  - Wedemeyer, H.
PY  - 2013
DO  - 10.1136/gutjnl-2013-305667
SN  - 0017-5749
UR  - https://hdl.handle.net/20.500.14352/114145
T2  - GUT
AB  - Background and aim Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and...
LA  - eng
M2  - 1150
PB  - BMJ
KW  - Anemia
KW  - Hepatitis C
KW  - Interferon
TI  - Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
TY  - journal article
VL  - 63
ER  -